| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Takeda103A targets GRK2, a kinase that plays a key role in the regulation of G protein-coupled receptors (GPCRs). It inhibits GRK2-dependent bovine tubulin oxidation.
|
|---|---|
| ln Vitro |
In vitro, Takeda103A is a potent and selective GRK2 inhibitor with an IC50 of 0.02 µM and 450-fold selectivity over GRK5. It is used to study GRK2-dependent signaling pathways.
|
| ln Vivo |
In vivo, Takeda103A has the potential for the research of heart failure. It is used to study the role of GRK2 in cardiovascular physiology and disease.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Takeda103A typically involve evaluating its inhibitory activity against purified GRK2 using kinase activity assays. IC50 values are determined by measuring residual kinase activity after incubation with varying concentrations of the compound.
|
| Cell Assay |
For in vitro cell-based assays, Takeda103A is dissolved in DMSO and applied to cultured cells at concentrations ranging from 1 nM to 10 µM. Effects on GPCR signaling, cell proliferation, or viability are assessed after 1-24 hours of treatment.
|
| Animal Protocol |
In vivo animal studies commonly use mouse models of heart failure. Takeda103A is administered orally or intraperitoneally at doses ranging from 1-50 mg/kg. Cardiac function is evaluated by measuring hemodynamic parameters, echocardiography, and molecular markers.
|
| ADME/Pharmacokinetics |
Takeda103A has a molecular weight of 463.49 g/mol and a molecular formula of C24H23F2N7O. It is soluble in DMSO.
|
| Toxicity/Toxicokinetics |
Takeda103A has a favorable safety profile with no significant toxicity reported at research doses. Its high selectivity for GRK2 over GRK5 minimizes off-target effects.
|
| Additional Infomation |
Takeda103A is a valuable tool compound for studying GRK2 signaling in cardiovascular research. It has potential therapeutic applications in heart failure and other conditions where GRK2 is dysregulated.
|
| Molecular Formula |
C24H23F2N7O
|
|---|---|
| Molecular Weight |
463.482530832291
|
| Exact Mass |
463.193
|
| CAS # |
865609-72-9
|
| PubChem CID |
11155477
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
34
|
| Complexity |
634
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCN1C(=NN=C1C2=NC=NC=C2)CNC3=CC=CC(=C3)C(=O)NCC4=C(C=CC=C4F)F
|
| InChi Key |
VWBSMGFTNCQOMB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H23F2N7O/c1-2-11-33-22(31-32-23(33)21-9-10-27-15-30-21)14-28-17-6-3-5-16(12-17)24(34)29-13-18-19(25)7-4-8-20(18)26/h3-10,12,15,28H,2,11,13-14H2,1H3,(H,29,34)
|
| Chemical Name |
N-[(2,6-difluorophenyl)methyl]-3-[(4-propyl-5-pyrimidin-4-yl-1,2,4-triazol-3-yl)methylamino]benzamide
|
| Synonyms |
Takeda 103 A; Takeda-103-A; Takeda103A
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1576 mL | 10.7880 mL | 21.5759 mL | |
| 5 mM | 0.4315 mL | 2.1576 mL | 4.3152 mL | |
| 10 mM | 0.2158 mL | 1.0788 mL | 2.1576 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
